Liminatus Pharma (LIMN) Cash from Investing Activities (2024 - 2025)
Liminatus Pharma (LIMN) posted Cash from Investing Activities of -$13108.0 for Q3 2025, up 93.45% sequentially from -$200000.0 in Q2 2025, and up 98.36% YoY from -$6608.1 in Q3 2024.
Liminatus Pharma (LIMN) Cash from Investing Activities (2024 - 2025) Analysis & Trends
Liminatus Pharma has reported Cash from Investing Activities for 2 years, with the latest figure at -$13108.0 in Q3 2025.
- Quarterly Cash from Investing Activities rose 98.36% year-over-year to -$13108.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$788108.0 (changed N/A YoY) and the FY2025 annual result came in at -$788108.0, up 72.35% from the prior year.
- Cash from Investing Activities advanced to -$13108.0 in Q3 2025 per LIMN's latest filing, from -$200000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$13108.0 in Q3 2025 and troughed at -$800000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Liminatus Pharma | 256.03 Mn | 256.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -13,108.00 |
| Sep 30, 2025 | -13,108.00 |
| Jun 30, 2025 | -200,000.00 |
| Jun 30, 2025 | -200,000.00 |
| Mar 31, 2025 | -575,000.00 |
| Mar 31, 2025 | -575,000.00 |
| Dec 31, 2024 | -550,000.00 |
| Dec 31, 2024 | -550,000.00 |
| Sep 30, 2024 | -800,000.00 |
| Sep 30, 2024 | -800,000.00 |